Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: Single center, 15-year experience

International Journal of Hematology

Volumn 91, Issue 1, 2010, Pages 78-86

  Zhai, Linzhu ^a   Guo, Chengcheng ^a   Cao, Yabing ^a   Xiao, Jian ^a   Fu, Xiaohong ^a   Huang, Jiajia ^a   Huang, Huiqiang ^a   Guan, Zhongzhen ^a   Lin, Tongyu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Doxorubicin; Efficacy; Non Hodgkin's lymphoma; Pirarubicin; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; PIRARUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART VENTRICLE CONTRACTION; HUMAN; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RETROSPECTIVE STUDY; SIDE EFFECT; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 75049084043     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0461-8     Document Type: Article

References (36)

1. F d'Amore H Brincker BE Christensen, et al. 1992 Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group Ann Oncol 3 379 386 1616892
2. AG Glass LH Karnell HR Menck 1997 The National Cancer Data Base report on non-Hodgkin's lymphoma Cancer 80 2311 2320 10.1002/(SICI)1097-0142(19971215)80: 12<2311::AID-CNCR13>3.0.CO;2-X 1:STN:280:DyaK1c%2FmslaisQ%3D%3D 9404709 (Pubitemid 28007403)
3. B Coiffier E Lepage J Briere, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 10.1056/NEJMoa011795 1:CAS:528: DC%2BD38XmslGgsw%3D%3D 11807147 (Pubitemid 34438862)
4. P Feugier A Van Hoof C Sebban, et al. 2005 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 4117 4126 10.1200/JCO.2005.09.131 1:CAS:528:DC%2BD2MXmt1elsr0%3D 15867204 (Pubitemid 46211317)
5. M Pfreundschuh L Trumper A Osterborg, et al. 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379 391 10.1016/S1470-2045(06)70664-7 1:CAS:528:DC%2BD28XjvFWlsbw%3D 16648042
6. M Pfreundschuh L Trumper M Kloess, et al. 2004 Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL Blood 104 634 641 10.1182/blood-2003-06-2095 1:CAS:528:DC%2BD2cXmtlCkt7Y%3D 15016643 (Pubitemid 38970554)
7. M Pfreundschuh L Trumper M Kloess, et al. 2004 Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood 104 626 633 10.1182/blood-2003-06-2094 1:CAS:528:DC%2BD2cXmtlCkt7k%3D 14982884 (Pubitemid 38970553)
8. DD Von Hoff MW Layard P Basa, et al. 1979 Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 710 717
9. M Mori K Kitamura M Masuda, et al. 2005 Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma Int J Hematol 81 246 254 10.1532/IJH97.03147 1:CAS:528:DC%2BD2MXkslGhur4%3D 15814336 (Pubitemid 41364491)
10. HQ Huang XB Lin ZH Pan, et al. 2007 CEOP regimen in the treatment for non-Hodgkin's lymphoma Zhonghua Zhong Liu Za Zhi 29 391 395 17892140
11. H Umezawa Y Takahashi M Kinoshita, et al. 1979 Tetrahydropyranyl derivatives of daunomycin and adriamycin J Antibiot (Tokyo) 32 1082 1084 1:CAS:528:DyaL3cXjsVSltQ%3D%3D
12. E Koh Y Ueda T Nakamura, et al. 2002 Apoptosis in young rats with adriamycin-induced cardiomyopathy-comparison with pirarubicin, a new anthracycline derivative Pediatr Res 51 256 259 10.1203/00006450-200202000-00021 1:CAS:528:DC%2BD38Xht1yktbk%3D 11809923
13. P Herait N Poutignat M Marty, et al. 1992 Early assessment of a new anticancer drug analogue-are the historical comparisons obsolete? The French experience with pirarubicin Eur J Cancer 28A 1670 1676 10.1016/0959-8049(92) 90066-B 1:STN:280:DyaK3s%2FgtFGntQ%3D%3D 1389483
14. D Dantchev M Paintrand M Hayat, et al. 1979 Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy J Antibiot (Tokyo) 32 1085 1086 1:STN:280:DyaL3c7hsFamsg%3D%3D
15. NL Harris ES Jaffe J Diebold, et al. 2000 The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, 1997 Hematol J 1 53 66 10.1038/sj.thj.6200013 1:STN:280:DC%2BD387oslCltg%3D%3D 11920170
16. TA Lister D Crowther SB Sutcliffe, et al. 1989 Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting J Clin Oncol 7 1630 1636 1:STN:280: DyaK3c%2FjvFCnsA%3D%3D 2809679
17. BD Cheson B Pfistner ME Juweid, et al. 2007 Revised response criteria for malignant lymphoma J Clin Oncol 25 579 586 10.1200/JCO.2006.09.2403 17242396 (Pubitemid 350002966)
18. HQ Huang YL Peng QQ Cai, et al. 2005 Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens Zhonghua Xue Ye Xue Za Zhi 26 577 580 16532963
19. S Ohga K Nakamura Y Shioyama, et al. 2005 Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy Radiat Med 23 156 161 15940061
20. T Nishioka K Tsuchiya S Nishioka, et al. 2004 Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck Int J Radiat Oncol Biol Phys 60 3 847 852 1:CAS:528:DC%2BD2cXotFCmtLg%3D 15465202
21. T Takagi C Sakai M Oguro 1990 Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin's lymphoma Oncology 47 25 28 10.1159/000226780 1:STN:280:DyaK3c7jslOgsw%3D%3D 2300381
22. H Tsurumi T Yamada M Sawada, et al. 2004 Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study J Cancer Res Clin Oncol 130 107 113 10.1007/s00432-003-0508-9 1:CAS:528: DC%2BD2cXhtlehsL8%3D 14648210 (Pubitemid 38316674)
23. Y Sato T Yamazaki K Yasukawa, et al. 1999 Cellular uptake and cytostatic activity of pirarubicin (THP) in T-lymphoma cells J New Remedies Clinics 48 327 334
24. VJ Ferrans JR Clark J Zhang EH Herman, et al. 1997 Pathogenesis and prevention of doxorubicin cardiomyopathy Tsitologiia 39 928 937 1:STN:280:DyaK1c7ms1aguw%3D%3D 9505340
25. I Muller D Niethammer G Bruchelt 1998 Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review) Int J Mol Med 1 491 494 1:CAS:528:DyaK1cXmvFWhtbY%3D 9852255
26. French Adjuvant Study Group 2001 Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial J Clin Oncol 19 602 611
27. MN Raber RA Newman K Lu, et al. 1989 Phase I clinical trial and pharmacokinetic evaluation of 4-0-tetrahydropyranyladriamycin (THP-adriamycin) Cancer Chemother Pharmacol 23 311 315 10.1007/BF00292410 1:STN:280: DyaL1M3gvFWjsw%3D%3D 2706737 (Pubitemid 19087691)
28. H Tsurumi T Hara N Goto, et al. 2007 A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma Hematol Oncol 25 107 114 10.1002/hon.815 1:CAS:528:DC%2BD2sXht1SrsbzP 17457949 (Pubitemid 47507877)
29. A Guerci P Lederlin F Reyes, et al. 1996 Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte Ann Oncol 7 966 969 1:STN:280:DyaK2s7lvFCjuw%3D%3D 9006749
30. N Niitsu M Nakayama M Umeda 1997 Usefulness of THP-COPBLM therapy in elderly patients with non-Hodgkin's lymphoma Gan To Kagaku Ryoho 24 1 61 66 1:STN:280:DyaK2s7ntlSkuw%3D%3D 9020947
31. K Kitamura F Takaku 1990 Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly Am J Clin Oncol 13 Suppl 1 S15 S19 2291455
32. S Mitsuhashi H Ninomiya A Shibuya, et al. 1993 Effect of THP-CVP regimen for elderly patients with malignant lymphoma Rinsho Ketsueki 34 1532 1539 1:STN:280:DyaK2c7isFGntw%3D%3D 8295326
33. N Niitsu M Umeda 1997 THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study Leukemia 11 1817 1820 10.1038/sj.leu. 2400001 1:CAS:528:DyaK1cXktF2ksr4%3D 9369412
34. G Mathe H Umezawa S Oka, et al. 1986 An oriented phase II trial of THP-adriamycin in breast carcinoma Biomed Pharmacother 40 376 379 1:STN:280:DyaL2s3hsVChtA%3D%3D 3580506
35. TM Habermann EA Weller VA Morrison, et al. 2006 Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 3121 3127 10.1200/JCO.2005.05.1003 1:CAS:528:DC%2BD28XnslKhsL4%3D 16754935 (Pubitemid 46638950)
36. H Nakada M Ogawa H Miyamoto, et al. 1984 Phase II study of 4-O-tetrahydropyranyladriamycin (THP-ADM) Gan To Kagaku Ryoho 11 138 142 1:STN:280:DyaL2c7is1yktg%3D%3D 6696455